Management of intractable hypoglycemia with Yttirum-90 radioembolization in a patient with malignant insulinoma

American Journal of the Medical Sciences

Volumn 340, Issue 5, 2010, Pages 414-417

  Chandra, Prakash ^a   Yarandi, Shadi Sadeghi ^a   Khazai, Natasha ^a   Jacobs, Sol ^a   Umpierrez, Guillermo E ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Hypoglycemia; Insulinoma; Malignant insulinoma; Octreotide therapy; Yttirum 90

Indexed keywords

CAPECITABINE; CORTICOSTEROID; DEXAMETHASONE; DIAZOXIDE; EVEROLIMUS; GLUCAGON; GLUCOSE; INDIUM 111; OCTREOTIDE; RAPAMYCIN; SUNITINIB; YTTRIUM 90;

ADULT; ARTICLE; ARTIFICIAL EMBOLISM; CANCER COMBINATION CHEMOTHERAPY; CASE REPORT; DRUG MEGADOSE; FEMALE; HUMAN; HUMAN TISSUE; HYPOGLYCEMIA; INSULINOMA; METASTASIS; MULTIPLE CYCLE TREATMENT; PANCREAS BIOPSY; PANCREAS RESECTION; THROMBOCYTOPENIA;

EID: 78349309297     PISSN: 00029629     EISSN: None     Source Type: Journal    
DOI: 10.1097/MAJ.0b013e3181ee7be2     Document Type: Article

References (27)

1. Kaltsas GA, Besser GM, Grossman AB. The diagnosis and medical management of advanced neuroendocrine tumors. Endocr Rev 2004; 25:458-511.
2. Starke A, Saddig C, Mansfeld L, et al. Malignant metastatic insuli-noma-postoperative treatment and follow-up. World J Surg 2005;29: 789-93.
3. Tucker ON, Crotty PL, Conlon KC. The management of insulinoma. Br J Surg 2006;93:264-75.
4. Kennedy AS, Dezarn WA, McNeillie P, et al. Radioembolization for unresectable neuroendocrine hepatic metastases using resin 90Y-micro-spheres: early results in 148 patients. Am J Clin Oncol 2008;31:271-9.
5. Ho KW, Wong CC, Balalla B, et al. Malignant insulinomas with hepatic metastases successfully treated with selective internal radiation therapy. Clin Endocrinol (Oxf) 2006;65:410-1.
6. Ong G, Henley D, Hurley D, et al. Therapies for the medical management of persistent hypoglycaemia in two cases of inoperable malignant insulinoma. Eur J Endocrinol 2010;162:1001-8.
7. Nakakura EK, Bergsland EK. Islet cell carcinoma: neuroendocrine tumors of the pancreas and periampullary region. Hematol Oncol Clin North Am 2007;21:457-73, viii.
8. Moertel CG, Lefkopoulo M, Lipsitz S, et al. Streptozocin-doxorubi-cin, streptozocin-fluorouracil or chlorozotocin in the treatment of ad-vanced islet-cell carcinoma. N Engl J Med 1992;326:519-23.
9. Cheng PN, Saltz LB. Failure to confirm major objective antitumor activity for streptozocin and doxorubicin in the treatment of patients with advanced islet cell carcinoma. Cancer 1999;86:944-8.
10. Rivera E, Ajani JA. Doxorubicin, streptozocin, and 5-fluorouracil chemotherapy for patients with metastatic islet-cell carcinoma. Am J Clin Oncol 1998;21:36-8.
11. Kouvaraki MA, Ajani AJ, Hoff P, et al. Fluorouracil, doxorubicin, and streptozocin in the treatment ofpatients with locally advanced and metastatic pancreatic endocrine carcinomas. J Clin Oncol 2004;22: 4762-71.
12. Kulke MH, Bergsland EK, Yao JC. Glycemic control in patients with insulinoma treated with everolimus. N Engl J Med 2009;360:195-7.
13. Bourcier ME, Sherrod A, DiGuardo M, et al. Successful control of intractable hypoglycemia using rapamycin in an 86-year-old man with a pancreatic insulin-secreting islet cell tumor and metastases. J Clin Endocrinol Metab 2009;94:3157-62.
14. Crutchlow MF, Bloom RD. Transplant-associated hyperglycemia: a new look at an old problem. Clin J Am Soc Nephrol 2007;2:343-55.
15. Wullschleger S, Loewith R, Hall MN. TOR signaling in growth and metabolism. Cell 2006;124:471-84.
16. Bussiere CT, Lakey JR, Shapiro AM, et al. The impact of the mTOR inhibitor sirolimus on the proliferation and function of pancreatic islets and ductal cells. Diabetologia 2006;49:2341-9.
17. Fraenkel M, Ketzinel-Gilad M, Ariav Y, et al. mTOR inhibition by rapamycin prevents beta-cell adaptation to hyperglycemia and exacer-bates the metabolic state in type 2 diabetes. Diabetes 2008;57:945-57.
18. YaoJC, Phan AT,ChangDZ,etal.Efficacy of RAD001 (everolimus) and octreotide LAR in advanced low-to intermediate-grade neuroen-docrine tumors: results of a phase II study. J Clin Oncol 2008;26: 4311-8.
19. Yao JC, Lombard-Bohas C, Baudin E, et al. Daily oral everolimus activity in patients with metastatic pancreatic neuroendocrine tumors after failure of cytotoxic chemotherapy: a phase II trial. J Clin Oncol 2010;28:69-76.
20. Modlin IM, Oberg K, Chung DC, et al. Gastroenteropancreatic neuroendocrine tumours. Lancet Oncol 2008;9:61-72.
21. Reubi JC. Peptide receptor expression in GEP-NET. Virchows Arch 2007;451(suppl 1):S47-50.
22. Stolz B, Weckbecker G, Smith-Jones PM, et al. The somatostatin receptor-targeted radiotherapeutic [90Y-DOTA-DPhe1, Tyr3]octreotide (90Y-SMT 487) eradicates experimental rat pancreatic CA 20948 tumours. Eur J Nucl Med 1998;25:668-74.
23. Kwekkeboom DJ, Mueller-Brand J, Paganelli G, et al. Overview of results of peptide receptor radionuclide therapy with 3 radiolabeled somatostatin analogs. J Nucl Med 2005;46(suppl 1):62S-6S.
24. Sato KT, Lewandowski RJ, Mulcahy MF, et al. Unresectable che-morefractory liver metastases: radioembolization with 90Y micro-spheres\safety, efficacy, and survival. Radiology 2008;247:507-15.
25. Andrews JC, Walker SC, Ackermann RJ, et al. Hepatic radioembo-lization with yttrium-90 containing glass microspheres: preliminary results and clinical follow-up. J Nucl Med 1994;35:1637-44.
26. King J, Quinn R, Glenn DM, et al. Radioembolization with selective internal radiation microspheres for neuroendocrine liver metastases. Cancer 2008;113:921-9.
27. Rhee TK, Lewandowski RJ, Liu DM, et al. 90Y Radioembolization for metastatic neuroendocrine liver tumors: preliminary results from a multi-institutional experience. Ann Surg 2008;247:1029-35.